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Summary.-Drug screening trials and general treatment of solid tumours in ad-
vanced cancer patients have been concerned only with the site of primary origin,
regardless of where metastases might have seeded. Since the environment for
tumour growth can differ appreciably at various anatomical sites, an investigation
was undertaken to determine the effect of metastatic site on response to chemo-
therapy. Data from 1961 to 1965 of the screening trials of the Eastern Clinical Drug
Evaluation Program were utilized. Response and location data extensive enough
for analysis represented 6 sites of primary origin and 6 metastatic site groups,
totalling 1687 lesions. Analysis of percentage reduction in tumour size after chemo-
therapy regimens of up to 60 days revealed a significant amount of variation asso-
ciated with metastatic sites and a non-significant amount associated with sites
of primary origin. Advanced primary tumours showed marked variation in
responsiveness and some showed a difference in response to different drug groups.
Generally, metastases responded better than the advanced primaries from which
they were derived, except for those from breast tumours.
CHEMOTHERAPY for patients with can-
cer in its more advanced stages, i.e.
with locally recurrent or metastatic
disease, is generally administered on the
basis of the site of primary origin. In
selecting drugs, little attention is given
to the location of the actual tumour to
be treated. This is clearly evident from
a voluminous literature of clinical trials
of anti-tumour agents wherein results
are subcategorized according to the pri-
mary site. In most cases the disease
being treated has spread to involve
different organs from the original primary
site. Indeed, it may not even be present,
having been excised when the disease
was diagnosed in its earlier localized
stages. The location of the measured
lesions from which the response rates
are calculated is seldom mentioned, except
occasionally in trials involving diseases
where the primary site has no specific
location, such as lymphomata. The in-
fluence of the metastatic site within
primary types of diseases has not been
examined, although a number of other
variables have been studied in an effort
to pinpoint the source of considerable
variation in response rates reported for
given anti-tumour agents for the various
primary tumour types (Brennan et al.,
1964; Schneiderman, 1962).
The current procedure for clinical
trials of anti-tumour agents, usually
referred to as Phase II Drug Screens,
is to administer test drugs to cancer
patients with advanced disease and evalu-
ate the proportion of responses, usually
within tumour types, from a given site
of primary origin. Tumours of a given
type of origin under observation may
be diversely located, but seldom is con-
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sideration given to the fact that their
growth patterns may be dependent more
on the environment of the metastatic
site than on the site of primary origin.
Breur (1966) observed that pulmonary
metastases from different sites of primary
origin grew at a constant rate. He also
observed a wide variation in growth
rates of metastases between patients
grouped within types of primary origin
Rambert et al. (1968) noted a wide
variation in doubling times between
metastatic tumours in different locations
within the same patient. In patients
with lung metastases he noted a wide
variation in doubling times for tumours
of similar histology, which is somewhat
contradictory to the observations of
Breur (1966).
Although the influence of the meta-
static site on tumour growth has not
been studied extensively, there is some
evidence that it may play more than a
minor role. If growth rates differ greatly
by location, the evaluation of cytotoxic
drugs, especially those that are dependent
on the cell cycle time, may be particularly
affected by the location distribution of
metastatic tumours being measured. This
problem has been examined using data
collected under the Eastern Clinical Drug
Evaluation Program (ECDEP) and the
findings are presented in this report.
MATERIALS AND METHOI)S
Data for this work were taken from
those collected under the Eastern Clinical
Drug Evaluation Program (ECDEP) from
September 1961 to December 1965. This
was a Phase II screening programme to
determine drug efficacy for a variety of
tumour types. Patients with advanced can-
cer, usually metastatic, with measurable
lesions were treated with one of several
drugs under trial. The drug for a given
patient was selected by the participating
physician with approval of the regional
office. When entries for a given drug-
tumour-type category became filled (the
desired minimum sample size per category
was 14 at the time), an alternate drug selec-
tion was requested. This is not the most
desirable from a statistical standpoint but
at the time it was the most workable ad-
ministratively. Patients were examined rou-
tinely for toxicity and tumour measurements
for at least 60 days. Treatment regimens
varied according to the drug, from as short
as 10 days for AB-132 to 60 days for 6-mer-
captopurine (6-MP). Other drugs used by
ECDEP were 5-fluorouracil (5-FU), chlor-
ambucil and mitomycin-C.
Details of the protocols and criteria of
response can be found in a report on 5-FU
from the ECDEP (Moore et al., 1968).
Details of other drug regimens and toxicities
etc. can be found in adjoining articles in
the same issue of Cancer Chemothorapy
Reports. Over 1600 acceptable patients were
evaluated in this programme and 1432 had
reliable information on the site of the
measured lesions, totalling 2702. This is
not an accounting of the total number
of lesions but only those measured in the
programme. Even patients with one mea-
sured lesion may have had multiple lesions
which were not measured because of location
or some other reason.
Though the majority of tumours being
measured in this programme were meta-
static, there were a fair proportion (19%)
that were the original primary tumours.
These were particularly prevalent in lung
cancer (see Table I), with the primary
representing half of the tumours. Because
of the nature of this disease, only about
25% of new diagnoses are operable. In
unoperable cases the primaries usually are
preferentially treated with radiotherapy, then
receive chemotherapy when they fail to
respond to irradiation, hence their appearance
in these data.
To evaluate the influence of metastatic
site on tumour growth and response to
chemotherapy independent from that of the
primary site, it is necessary to have a group
or groups of lesions representing several
primary sites, each of which has tumours
in the various metastatic locations. In
other words, for the most informative and
reliable analysis there should be a minimum
of empty data cells in a cross-classification
table of the variables under study. In
these data more than one-third of the
lesions were distributed among 23 of the
less common primary sites, most of which
did not have a representation of metastatic
lesions in all the locations under study.
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These have not been included in these
analyses. Nearly two-thirds of the lesions
were distributed among 10 of the primary
sites. Even among these the distributions
of metastatic sites required considerable
collapsing to reduce the number of empty
data cells.
Some of the primary sites were con-
solidated. These included a GI category
composed of stomach, colon and rectum;
and a GYN category composed of ovary,
cervix and uterus. Other primary sites
included in most analyses were mouth-
pharynx-larynx (MPL) which were always
recorded as one in the ECDEP, lung, breast,
and melanoma. Consolidation of metastatic
sites was also necessary. Categories used
in most analyses consisted of lesions in the
integumentary system, skeletal system, res-
piratory which was primarily lungs, haemato-
logical and lymphatic system which was
primarily lymph nodes, and the digestive
system which consisted mostly of liver and
some epigastrium lesions. With this con-
solidation, the number of empty data cells
was reduced to a minimum. It was impos-
sible to eliminate them altogether and main-
tain a meaningful categorization for analysis.
(Note the two empty cells in the overall
distribution of metastases by primary site
in Table I.) Several others occurred when
the data were dicotomized into drug groups,
all but two of which were eliminated by
the further consolidation of " skeletal " and
"digestive " metastases (see Table V).
The dependent variable used to represent
lesion response to chemotherapy was the
percentage change in cross-sectional area.
All changes were determined by comparing
the pretreatment measurements with the
smallest size attained in the 60-day period.
If the lesion never regressed, the largest
size attained in 60 days was used.
Preliminary analyses were based on the
" response rate " often used in the ECDEP
reports, namely the percentage of patients
whose tumours showed at least a 50%
reduction in cross-sectional area. In subse-
quent analyses the " ridit " of the response
was used since this takes into account the
full range of size changes. The " ridit "
analysis is explained further in the statistical
appendix.
RESULTS
Preliminary analysis
A cross-classification of the more
common primary sites and metastatic
sites is shown in Table I. It is apparent
from the distribution of metastatic sites
within each primary site that there is a
substantial difference in where metastases
tend to appear. These distributions can-
TABLE I.-Distribution of Major Areas of Metastasisfor Some of the More Common
Primary Sites
Primary sites
-k I
Metastatic system
or site
Integumentary
Skeletal
Respiratoryd
Haemic and lymphatic
Digestivee
Primaryf
Other
Total 211 445 135 433 274
a MPL = Mouth, pharynx, or larynx.
b GI = Stomach, large intestine, or rectum.
c GYN = Cervix, uterus, or ovary.
cl Respiratory consists of lung primarily.
c Digestive consists of liver and epigastrium.
f " Primary " indicates the measured lesion
table).
189 1687
was the primary lesion (as indicated across the top of
MPLa
No. %
115 54
7 3
28 13
35 17
24 11
2 1
Glb
No. %
71 16
108 24
26 6
143 32
75 17
22 5
Lung
No. %
25 19
4 3
13 10
20 15
2 1
68 50
3 2
Breast
No. %
173 40
63 15
63 15
47 11
18 4
65 15
4 1
GYNc
No. %
56 20
7 3
72 26
23 8
15 5
77 28
24 9
Melanoma
,1
No. %
107 57
5 3
45 24
7 4
5 3
18 10
2 1
Total
547
86
329
158
183
327
57
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TABLE II.-Number ofPatients andResponse Rate (50% Criterion) by Site or Origin and
Site of Measured Lesionfor Some of the More Common Site8
Site of origin
Site of measured
lesion
Integumentary
Skeletal
Respiratory (lung)
Lymph nodes
Digestive (liver,
epigastrium)
Primary
Total
MPL
Pts %R
115 25
7 14
28 29
35 26
GI
Pts %R
71 32
108 9
26 65
143 26
Lung
Pts %R
25 52
4 0
13 0
20 45
2 0
Breast
Pts %R
173 24
63 6
63 10
47 34
18 22
GYN
Pts %R
56 25
7 14
72 14
23 35
15 33
Melanoma
Pts %R
107 23
5 20
45 13
7 43
5 40
Total
Pts %R
547 27
86 8
329 12
158 39
183 26
24 12 75 16 68 12 65 40 77 27 18 22 327 23
209 24 423 23 132 23 429 23 250 24 187 22 1630 23
not be interpreted as representative of
the true metastatic pattern because in
the original trials of the ECDEP there
was no effort made to record all lesions
for a given patient. Skeletal lesions in
particular were often not recorded because
of the difficulty in obtaining reliable
measurements. Nevertheless, it is ap-
parent that if differences in growth and
response at different metastatic sites
exist, such divergent distributions among
data series around the country could
influence chemotherapy recommendations
for some types of tumours. Superficial
tumours in the integumentary system,
for example, may be more responsive
than other tumours. They comprised
over half of all measured lesions for
primary MPL tumours and melanomata,
and 40% for primary breast tumours.
A general impression of the respective
roles of the site of origin and the site
of measured lesion can be obtained from
Table II, which shows the distribution
of patients over sites and the response
rate in each cross-category. The response
rate in Table II is the percentage of
patients showing a 50% reduction in
tumour size.
The response rates for the marginal
totals of the rows and columns of Table
II are based on fairly sizable series and
tell a more coherent story than the
response rates in the body of the table,
since these are sometimes based on only
a few patients. Glancing down the mar-
ginal totals for the rows, for the sites
of the measured lesions it can be seen
that there is a relatively wide range
of response rates. For the overall re-
sponses to the 4 drugs under test from
all sites of origins and all metastatic
sites included in Table II, the response
rate is 23%. The range for row totals
is from a low of 8% and 12% for skeletal
and respiratory lesions respectively, to
a high of 39% for the lymph node lesions.
This suggests that there are differential
response rates for the different sites of the
measured lesions.
By contrast, the response rates of
the marginal totals for the columns, the
sites of origin, are surprisingly uniform.
They range only from a low for melanoma
of 22% to a high for MPL and GYN of
24%. There is no suggestion in these
totals that the site of origin has any
important effect on the response rate.
When the range of column rates is
compared with the range of the row rates
there is a clear impression that the site
of the measured lesion has more influence
on the response rates than the site of
origin.
The results here appear to contradict
a widely accepted chemotherapeutic doc-
trine that has long been the basis for
the design of studies for the evaluation
of new chemotherapeutic agents, particu-
larly the Phase II studies based on
metastatic lesions. In the ECDEP the
analysis was based on site of origin and
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the inferences were drawn with respect
to efficacy of drugs for particular sites
of origin. Before calling into question
an approach that has been used for many
years, it is important to consider the
possibility that there may be artefacts
or other factors which are masking the
effects ofthe site oforigin in the marginals
of Table II.
One possibility is that there are
particular combinations of sites of origin
and sites of measured lesion where the
drugs tend to be effective or ineffective
and that these happen to have balanced
out for the columns and not in the rows.
In other words, the result might be
explained by a strong interaction between
the two factors. There is some suggestion
of an interaction in Table II, as can be
seen by looking across the response rates
in the rows. For example, the integu-
mentary sites show a range from 23%
to 52% with the highest response in
tumours originating in the lung. The
high value also stands out in looking
down the column for lung as site of
origin since the response rates (with one
other exception) tend to be low. Another
striking example of an interaction occurs
in the row where the site of measured
lesion is the primary and the range is
from 12% to a high of 4000 for tumours
where the breast is the site of origin.
Another possible objection to accepting
at face value the uniformity of the
site-of-origin response rates in the column
totals is that the results for all of the
drugs tested are combined in Table II.
This might be masking the importance
of the site of origin if the response at
different sites is markedly different for
each drug. In other words, a strong
interaction between drugs and site-of-
origin might be masked by combining
over drugs. Yet another objection might
be that the argument so far has been
impressionistic and based on casual in-
spection rather than a formal statistical
analysis.
One way to meet these objections and
to get further insight into the respective
roles of the site of origin, site of measured
lesion and drug in this complex interactive
situation, is to use a somewhat more
complicated type of statistical analysis.
To take advantage of the entire range
of response (rather than relying on an
arbitrary 50%/o reduction criterion), the
" ridit " of the response can be used to
provide a more quantitative index. An
analysis of variance gives a more formal
approach to the testing of hypotheses
about the interactions of the factors.
The details can be found in the statistical
appendix and the next section will present
the main results.
One question of interest in its own
right will be considered first: How do
the response rates in the primary and
the metastases from this site of origin
compare? Overall results are shown in
Table III. For some sites there are
marked differences in response rates
between the primary and the metastatic
lesions, a point that raises some question
about common practice of extrapolating
from the latter to the former when
Phase II studies are used to pick drugs
TABLE III.-Proportion ofRespon8e8 (50%
Criterion) for Primary and Meta8tatic
Tumours
Origin of
primary
MPL
Stomach
L. Intestine
Rectum
Lung
Breast
Cervix
Ovary
Kidney
Bladder
Melanoma
Connective tissue
Undetermined
Total
Primary
tumours
R/Ta %
3/24
9/39
3/25
0/11
8/68
26/65
11/45
9/28
0/4
7/16
4/18
4/27
1/7
12-5
23- 1
12-0
0
11-8**
40 0**
24-4
32-1
0
43-8
22-2
14-8
14-2
Metastatic
tumours
R/T %
47/187
25/67
47/186
19/117
22/67
73/368
17/85
18/80
12/96
6/15
37/171
31/184
43/184
25- 1
37-3
25-3
16-2
32-8
19-8
20-0
22-5
12-5
40 0
21-6
16-8
23-3
85/377 22-5 397/1807 22 0
a Responding (50%reduction) tumours over total
number measured.
** Proportions significantly different from those
of metastatic tumours for same site of origin
(P < 0- 01).
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for earlier stages of the disease. B
the response pattern of primar,
metastatic lesions appeared differel
analysis of response ridits was don
this factor kept separate.
A number ofother preliminary aI
were carried out on tumour re
rates to determine what variables
be important for inclusion in the
detailed analysis of response ridits
mour size did not appear to be an
tant factor but the drugs used
programme did appear to be imp
Response patterns and levels were
for mitomycin-C and 5-FU, ar
AB-132 and chlorambucil; hence
two groups of two drugs each wer
in the analysis. Data for 6-MP sh
different pattern oflow level respon
Mean ridit
Correspon(ling percentage reduction
z
ui
L)
D
many missingcells, hencewasnot included.
Analysis of response ridits
The results of the analysis are sum-
marized in the customary analysis of
variance table (Table IV), and are discus-
sed in terms that are as free of jargon as
possible. The analysis of the measured
lesions that were advanced primaries was
p3rformed separately (lines (L) 1-5 in Table
IV) from that of the metastatic lesions
(L 6-14 in Table IV).
The analysis of advanced primaries
showed the various tumour types to
have markedly different mean responses
(significant F ratio in L 2), as
might be expected. Mean values for
the different tumour types were as
follows:
Responsiveness of advanced primaries
MPL GI Lung Breast GYN
0-709 0-503 0 586 0 400 0 528
20% 24% 150% 34% 21%
Melanoma
0 566
17%
-- 1.000
- .891
.789
, .666
.584
.1458 a
- .357
.280
.180
-100 -60 -20 0 20 100 140 180 220
TUMOUR RESPONSE (%/6)
FIG. Identified distribution for ridit calculations based on tumour response of 5-fluorouracil.
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TABLE IV. Analysis of Variance of Response Riditsfor Primary Measurement
Sites andfor Metastatic Measurement Sites
Source of variation
Total
Site of origin
Drugs (D)
O x D
Within
Degrees of Sum of Mean F
freedom squares square ratio
Analysis of primary measurement sites
279 23 -4463
(0) 5 1*5144
1 0- 0861
5 2 0453
268 19-8004
0 3029
0 0861
0-4091
0 0739
Analysis of metastatic measurement sites
Total
Drugs (D)
Site of origin (0)
Site of measurement (M)
D x O
D x M
O x M
D x O x M
Within
11:
104
13 96- 3261
1 1- 3705
5 0 7330
3 3- 2238
5 1- 9058
3 0 0232
15 3- 8539
15 6- 5543
66 78- 6616
1 - 3705
0- 1466
1- 0746
0- 3812
0 0077
0 2569
0 4370
0 0738
* Statistically significant effect (P < 0-01).
It may facilitate interpretation to
convert these ridit values back to per-
centage reductions in tumour size (see
Fig.). The above values convert to
approximately a typical reduction of
about 34%0 for breast primaries, 24%
for GI primaries, and so on down to
zero mean response for MPL primaries.
There was no significant overall effect
of drugs, as grouped in this analysis,
on primary tumour types but some
tumour types responded differently on
the 2 drug groups, as indicated by the
significant interacting term in line 4.
The mean response ridits for the different
tumour types for each of the 2 drug
groups are shown in the top section of
Table V. Primary breast and gynaeco-
logical tumours responded best to AB-132
andchlorambucilwhile advanced primaries
at the other sites responded best to
mitomycin-C and 5-FU, though for neither
drug group did the other sites (except
GI) indicate promising activity. In fact,
many of the metastatic sites responded
better than these advanced primaries,
as is evident from the mean responses
in the bottom portion of Table V and
as was evident from preliminary analyses
discussed previously with Tables II and
III. In summary, the analysis of the
advanced primaries showed that the
location of the primary had a marked
effect on the mean response and indicated
which drug showed promising activity.
The analysis ofthe metastatic tumours
revealed that the metastatic (measure-
ment) site influenced mean response
strongly whereas the site of the primary
from which the metastasis was derived
did not. (Note the significant F ratio
in line 9 and the non-significant ratio
in line 8.) This effect can be seen by
examining the " all sites " column and
row in Table VI. Tumours metastatic
to the more superficial areas such as the
integumentary system and lymph nodes
showed good mean responses, whereas
those metastatic to deeper organ sites
such as in the respiratory, skeletal or
digestive systems showed poorer responses.
The range of differences among these
sites was considerably greater than among
those for site-of-origin, although the
variation seen in Table VI is not as good
a measure of the actual difference in
variation as the relative magnitude of
the sums of squares in lines 8 and 9
of Table IV. The column mean for
" lung " in particular is misleading unless
LI
L2
L3
L4
L5
L6
L7
L8
L9
L1O
Lll
L12
L13
L14
4- 10*
1-17
5-54*
18- 57*
1.99
14- 56*
5-16*
010
3-48*
5-92*
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'TABLE V.-Mean Response Ridits ofSite of Measuremient by Site ofOrigin by
Drt"g Groulp for Analysis ofPrimaries and of Metastases
Drug group
Site of measuremenit
Mito-C + 5-FU
AB-132 + Chlor.
(Ridits x 1000)
Site of oiigin
,~~~~~~~~
MPL GI Lung Breast GYN
Analysis of primary measurement sites
637 451 581 419 559
756 580 594 360 506
Ainalysis of metastatic measuremenlt sites
All primary
Melainoma sites
536 508
771 544
Mito-C + 5-FU (Group A)
Integumentary 485
Respiratory 440
Lymph nodes 444
Skeletal and (ligestive 729
All metastatic sites 487
AB-132 + Chlorambucil (Group B)
Integumentary 549
Respiratory 575
Lymph nodes 624
Skeletal and digestive
All metastatic sites 570
TABLE VI. Mean Re8ponse Ridits ofSite of Meaisurernent by Site of Origin
Site of
measuremenit
Iiitegumentary
Respiratory
Lymph nodes
Skeletal and digestive
All metastatic sites
MPL
510
489
520
729
518
GI
464
607
315
465
497
one takes into account the small numbers
involved, as shown in both Tables I
and II.
The mean response rates of metastatic
tumours were markedly different for the
2 drug groups. The mean response ridits
were 484 for mitomycin-C + 5-FU and
554 for AB-132 + chlorambucil, corres-
ponding to typical reductions of about
25% and 15% respectively.
So much for the mean response of
metastatic tumours: it depends far more
strongly on where the metastasis is than
on the site of the primary from which
it originated. What, however, about the
choice of which drug to use? Lines 10
and 11 of Table IV suggest that this
depends almost entirely on the site of
origin rather than on the site of the
metastasis. This dependence can be seen
(Ridits x 1000)
Site of origin
Lung Breast
347 479
696 584
377 457
602 645
453 533
GYN
455
589
482
368
500
Melanoma
518
646
700
423
560
All primary
sites
481
599
446
515
515
by examining the 2 " all sites " rows in
Table V. Four of the sites (MPL, GI,
lung and breast) had better mean responses
for mitomycin-C + 5-FU than for AB-
132 + chlorambucil, while for the re-
maining sites, particularly melanoma, the
opposite was true. Nevertheless, al-
though this observation is consistent with
the current aims of the Phase II drug
screening programme, the highly signifi-
cant D x 0 x M interaction in line 13
of Table IV warns us that the site of a
metastasis does in fact have some rele-
vance to the question of the drug to
which it is likely to be most responsive.
The interpretation of the large sum of
squares in line 13 is moot. On the one
hand, it could be due to the inadequacy
of the additive linear model or to the data
themselves, such as the non-randomness
441
570
220
407
456
493
665
384
562
558
257
782
285
473
313
537
680
521
666
603
430
503
344
662
484
537
631
583
625
584
422
582
570
421
511
468
594
387
211
492
545
676
700
396
591
478
584
449
507
455
573
396
483
484
513
628
506
565
554
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of the drug used. On the other hand
again, it could be due to real effects.
For example, in the bottom portions of
Table V note that for tumours of MPL
origin metastatic to lymph nodes or the
respiratory system, the mean responses
were good in the mitomycin-C + 5-FU
drug group but poor in the AB-132 +
chlorambucil group.
DISCUSSION
It is apparent from these data that
the mean response rate (as assessed by
the percentage reduction in the size
of a metastatic tumour after up to 60
days of chemotherapy) depends far more
strongly on the site of the metastasis
than on the site of the primary from
which it was derived. This has important
implications for both analysing data
from and designing trials for the drug
screening programmes. Depending upon
the distribution of measured lesions in
the sample of patients under trial, the
proportion of responses, and hence the
indication of drug activity for a given
type of tumour, could be demonstrably
affected. With a few exceptions, the
superficial lesions such as lymph nodes
and those in the integumentary system
tended to be responders; and the deep
lesions such as those in the skeletal and
respiratory systems tended to be non-
responders. Furthermore, it was appa-
rent that the metastatic lesions that do
respond do not give a reliable indication
of drug action against parent tumour
types.
This investigation was supported in
partby the U.S. Public Health Service Re-
search Grant No. CA-10378 from the
National Cancer Institute.
STATISTICAL APPENDIX
Ridits-.The dependent variable used in
these analyses was obtained by converting
lesion measurement changes to ridits. The
term "ridit " stands for Relative to an
Identified Distribution and may have a
value from 0 to 1. The identified distribu-
tion (ID) can be any subseries or even the
total, though most preferably a control
series. In these analyses the distribution
of lesion changes for 5-FU was used, since
this drug has been tested on most tumour
types and has been approved for general
use. A detailed description of ridit calcula-
tions can be found in a paper by Bross
(1958). Essentially they use the cumulative
frequency distribution ofthe variable selected
for the ID. In this case the maximum
percentage change (relative to pretreatment
measurement) in cross-sectional area for
each lesion from patients treated with 5-FUT,
from complete regression (--100%) to the
largest progression (+20500,), was used
(see Fig.) and the ridits calculated. The
conversion to ridits puts the entire range
of response between zero and one and in a
form that can be handled by conventional
analyses.
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